GoodRx Q2 Snapshot: In-Line EPS, Better Revenue, and a Bigger Upgrade Story

GoodRx Q2 results improved the setup, but the real story is the business mix

GoodRx's latest quarter was more than a quiet beat. The company reported EPS of $0.08, slightly above consensus, and revenue ahead of Wall Street's expectations. It also used that momentum to raise full-year revenue guidance to $775 million. For investors, the bigger takeaway is that the quarter reinforced the case for viewing GoodRx as more than a coupon-discount app.

Clean print or a durable mix shift?

The cleanest read on the quarter is the mix. In Q2, Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-over-Year. That matters because those businesses sit closer to the commercial core of the platform, rather than relying only on savings search activity.

The bullish read is that GoodRx is proving it can monetize healthcare demand at multiple points in the user journey. The cautious read is that one strong quarter does not yet prove a permanent turnaround, especially with the slower top-line growth the company showed earlier in the year.

Pharma Direct and subscriptions are driving the operating mix

That mix shift is why the quarter matters. In Q2, Pharma Direct revenue increased 76% and Subscription revenue increased 39%, both year over year. Coming after Pharma Direct revenue increased 82% in Q1, the trend suggests these segments are doing more of the heavy lifting than they did in prior periods.

Why the mix matters for valuation

First, Pharma Direct gives GoodRx a more direct B2B monetization path through pharma manufacturers and other business customers, including consumer direct pricing. That can make revenue less dependent on one-off consumer coupon behavior and more tied to broader healthcare marketing and treatment budgets.

Second, subscriptions broaden wallet share. GoodRx is no longer waiting for a user to search for a single drug price. With offerings such as GoodRx Companion, a $14.99-per-month membership that includes medications, online care, and savings across dental, vision, labs, and imaging, the company is aiming for more recurring revenue. That tends to be stickier and less exposed to swings in any one drug category.

If those faster-growing lines continue to gain share, the market may increasingly value GoodRx on revenue quality and platform breadth rather than on a low-multiple coupon-aggregator framework.

November earnings will test whether the mix shift is durable

A better story only matters if the next report confirms it. The recent beat and raised full-year guidance changed the setup, but they did not settle the debate. On Nov. 3, 2026, investors will be looking for evidence that GoodRx is moving from a promising mix shift to a more durable growth and profitability profile.

The evidence investors still need

The cautious case is not theoretical. In Q1, revenue of $194.0 million still fell 4.4% year over year. That is the boundary condition for the current upgrade thesis.

So the November debate is fairly narrow: investors need to see whether revenue growth improves sustainably and whether Pharma Direct and subscription momentum continue to strengthen the overall business, rather than producing another isolated beat. If that confirmation shows up, the current rerating narrative becomes easier to defend.